立体定位放射治疗（Stereotactic body radiation therapy, SBRT）在少进展非小细胞肺癌（non-small-cell lung cancer, NSCLC）中的作用尚存在争议。我们评估了SBRT在少进展或少复发NSCLC患者亚型中是否提供持久反应，避免改变全身治疗的需求。我们进行了168例NSCLC患者的回顾性分析，这些患者接受了SBRT治疗以治疗少进展或少复发的疾病。少进展被定义为在全身治疗后或在全身治疗之后，出现≤5个病灶的进展，而最初是完全缓解或部分缓解。少复发被定义为在全身治疗期间发生进展。我们估计了无进展生存期（progression-free survival, PFS）、总生存期（overall survival, OS）和下一次治疗或死亡时间（time to next treatment or death, TNT-D）。 中位年龄为68岁。67%的患者在进展时正在接受全身治疗。31%的患者在原发部位存在进展。76%的患者转移进展的部位为0到2个，24%的患者为3到5个。2年OS和PFS分别为56%（95%CI 46%-64%）和14%（95%CI 8%-21%）。中位TNT-D为9个月（95%CI 6-11）。未观察到4级或5级的毒性。在多因素分析中，与0到2个转移部位的患者相比，有3到5个转移部位的患者具有更差的OS（HR 2.6, 95%CI 1.5-4.3, P < .001）和较短的TNT-D（HR 1.7, 95%CI 1.1-2.5, P = .01）。 SBRT是少进展和少复发NSCLC的一种安全可行的治疗选择。0到2个病灶的患者具有较好的OS和较长的TNT-D，而相比之下，有3到5个病灶的患者的情况较差。 版权所有 © 2023 Elsevier Inc. 保留所有权利。

The role of stereotactic body radiation therapy (SBRT) in oligoprogressive non-small-cell lung cancer (NSCLC) is controversial. We evaluated whether SBRT in a subset of patients with oligoprogressive or oligorecurrent NSCLC offers a durable response, obviating the need to change systemic therapy.A retrospective analysis of 168 NSCLC patients who underwent SBRT for oligoprogressive or oligorecurrent disease was performed. Oligoprogression was defined as progression in ≤5 lesions during or after systemic therapy following an initial complete or partial response. Oligorecurrence was defined as progression while off systemic therapy. Progression-free survival (PFS), overall survival (OS) and time to next treatment or death (TNT-D) were estimated.Median age was 68 years. Sixty-seven percent of patients were on systemic therapy at the time of progression. Progression at the primary site was present in 31% of the patients. The number of sites of metastatic progression was 0 to 2 in 76% and 3 to 5 in 24% of the patients. Two-year OS and PFS were 56% (95%CI 46%-64%) and 14% (95%CI 8%-21%), respectively. Median TNT-D was 9 months (95%CI 6-11). No grade 4 or 5 toxicity was seen. In multivariable analysis, patients with 3 to 5 sites of metastatic progression had worse OS (HR 2.6, 95%CI 1.5-4.3, P < .001) and shorter TNT-D (HR 1.7, 95%CI 1.1-2.5, P = .01) than those with 0 to 2 sites.SBRT is a safe and viable treatment option for oligoprogressive and oligorecurrent NSCLC. Patients with 0 to 2 sites had better OS and longer TNT-D compared to those with 3 to 5 lesions.Copyright © 2023 Elsevier Inc. All rights reserved.